Al‐Ola Abdallah

2.6k total citations
134 papers, 871 citations indexed

About

Al‐Ola Abdallah is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Al‐Ola Abdallah has authored 134 papers receiving a total of 871 indexed citations (citations by other indexed papers that have themselves been cited), including 97 papers in Hematology, 69 papers in Oncology and 56 papers in Molecular Biology. Recurrent topics in Al‐Ola Abdallah's work include Multiple Myeloma Research and Treatments (81 papers), CAR-T cell therapy research (34 papers) and Protein Degradation and Inhibitors (34 papers). Al‐Ola Abdallah is often cited by papers focused on Multiple Myeloma Research and Treatments (81 papers), CAR-T cell therapy research (34 papers) and Protein Degradation and Inhibitors (34 papers). Al‐Ola Abdallah collaborates with scholars based in United States, United Kingdom and Canada. Al‐Ola Abdallah's co-authors include Nausheen Ahmed, Joseph P. McGuirk, Ghulam Rehman Mohyuddin, Leyla Shune, Douglas W. Sborov, Zahra Mahmoudjafari, Shebli Atrash, Brian McClune, Hamza Hashmi and James A. Davis and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Al‐Ola Abdallah

107 papers receiving 855 citations

Peers

Countries citing papers authored by Al‐Ola Abdallah

Since Specialization

Citations

This map shows the geographic impact of Al‐Ola Abdallah's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Al‐Ola Abdallah with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Al‐Ola Abdallah more than expected).

Fields of papers citing papers by Al‐Ola Abdallah

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Al‐Ola Abdallah. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Al‐Ola Abdallah. The network helps show where Al‐Ola Abdallah may publish in the future.

Co-authorship network of co-authors of Al‐Ola Abdallah

This figure shows the co-authorship network connecting the top 25 collaborators of Al‐Ola Abdallah. A scholar is included among the top collaborators of Al‐Ola Abdallah based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Al‐Ola Abdallah. Al‐Ola Abdallah is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and Safety of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Multicenter Real-World Experience 2025 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), (unknown), Razan Mansour, (unknown), Nausheen Ahmed, Muhammad Umair Mushtaq, (unknown), Kimberly M Green, James A. Davis, Barry Skikne, Zahra Mahmoudjafari, (unknown), Shebli Atrash, Al‐Ola Abdallah	0
2	Impact of Frailty on Outcomes after CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma 2024 ·Transplantation and Cellular Therapy ·James A. Davis, Danai Dima, Nausheen Ahmed, (unknown), Joseph P. McGuirk, Jack Khouri, Jason Valent, Faiz Anwer, Al‐Ola Abdallah, Hamza Hashmi	1
3	P-079 Real-World Safety and Efficacy of Talquetamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Hira Shaikh, (unknown), (unknown), (unknown), James A. Davis, (unknown), (unknown), Nausheen Ahmed, (unknown), (unknown), (unknown), (unknown), Kimberly Green, (unknown), Muhammad Umair Mushtaq, (unknown), Al‐Ola Abdallah, Christopher Strouse, Hamza Hashmi, Shebli Atrash	1
4	Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial 2024 ·Blood ·(unknown), (unknown), (unknown), (unknown), (unknown), Hira Shaikh, Christopher Strouse, James A. Davis, (unknown), Kevin Graf, Kimberly M Green, Muhammad Umair Mushtaq, Zahra Mahmoudjafari, Hamza Hashmi, Joseph P. McGuirk, Al‐Ola Abdallah, Shebli Atrash, Abdullah Khan, Nausheen Ahmed	1
5	Correlates of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation 2024 ·Blood ·(unknown), Moazzam Shahzad, (unknown), Muhammad Kashif Amin, Sibgha Gull Chaudhary, (unknown), (unknown), Rajat Bansal, Al‐Ola Abdallah, Anurag K. Singh, Joseph P. McGuirk, Muhammad Umair Mushtaq	1
6	Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab‐naïve relapsed multiple myeloma 2024 ·European Journal Of Haematology ·Danai Dima, Razan Mansour, James A. Davis, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Nausheen Ahmed, Al‐Ola Abdallah, Hamza Hashmi	2
7	Outcomes with HLA-matched unrelated donor versus haploidentical hematopoietic cell transplantation 2024 ·Leukemia & lymphoma ·Muhammad Umair Mushtaq, Moazzam Shahzad, Muhammad Kashif Amin, Forat Lutfi, (unknown), (unknown), Kevin Li, Nausheen Ahmed, Rajat Bansal, Haitham Abdelhakim, Leyla Shune, Al‐Ola Abdallah, Sunil Abhyankar, Joseph P. McGuirk, Anurag K. Singh	2
8	Impact of Frailty on Outcomes after Chimeric Antigen Receptor T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma 2023 ·Transplantation and Cellular Therapy ·James A. Davis, Danai Dima, Nausheen Ahmed, (unknown), Joseph P. McGuirk, Xuefei Jia, Shahzad Raza, Jack Khouri, Jason Valent, Faiz Anwer, Al‐Ola Abdallah, Hamza Hashmi	18
9	Impact of Frailty on Outcomes after CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma 2023 ·Blood ·James A. Davis, Danai Dima, Nausheen Ahmed, (unknown), Joseph P. McGuirk, Jack Khouri, Jason Valent, Faiz Anwer, Al‐Ola Abdallah, Hamza Hashmi	2
10	“Waitlist mortality” is high for myeloma patients with limited access to BCMA therapy 2023 ·Frontiers in Oncology ·Nausheen Ahmed, (unknown), Muhammad Umair Mushtaq, Rajat Bansal, Haitham Abdelhakim, (unknown), (unknown), (unknown), Anurag K. Singh, Sunil Abhyankar, Siddhartha Ganguly, Joseph P. McGuirk, Al‐Ola Abdallah, Leyla Shune	10
11	Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy 2023 ·Transplantation and Cellular Therapy ·James A. Davis, Douglas W. Sborov, (unknown), (unknown), Al‐Ola Abdallah, Joseph P. McGuirk, Nausheen Ahmed, Hamza Hashmi	27
12	Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell Therapy Access 2022 ·Transplantation and Cellular Therapy ·Nausheen Ahmed, Moazzam Shahzad, Ernie Shippey, Rajat Bansal, Muhammad Umair Mushtaq, Zahra Mahmoudjafari, Muhammad Salman Faisal, Marc Hoffmann, Al‐Ola Abdallah, Clint Divine, Mehdi Hamadani, Joseph P. McGuirk, Leyla Shune	77
13	Time‐to‐event surrogate end‐points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis 2022 ·British Journal of Haematology ·(unknown), (unknown), Douglas W. Sborov, Brian McClune, Vinay Prasad, Alyson Haslam, (unknown), Christopher M. Booth, Samer Al Hadidi, Al‐Ola Abdallah, Aaron M. Goodman, Ghulam Rehman Mohyuddin	10
14	Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015–2020 2022 ·Blood Cancer Journal ·Oliver Van Oekelen, Nicole Birrer, (unknown), (unknown), Edward R. Scheffer Cliff, Aaron M. Goodman, Al‐Ola Abdallah, Rajshekhar Chakraborty, Vinay Prasad, Ghulam Rehman Mohyuddin	3
15	Palliative care utilization, transfusion burden, and end‐of‐life care for patients with multiple myeloma 2022 ·European Journal Of Haematology ·(unknown), (unknown), (unknown), (unknown), Al‐Ola Abdallah, Nausheen Ahmed, Leyla Shune, Douglas W. Sborov, Amandeep Godara, Brian McClune, Christian T. Sinclair, Ghulam Rehman Mohyuddin	6
16	Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: A systematic review 2021 ·American Journal of Hematology ·Ghulam Rehman Mohyuddin, (unknown), Al‐Ola Abdallah, Douglas W. Sborov, S. Vincent Rajkumar, Shaji Kumar, Brian McClune	17
17	Intention to treat versus modified intention-to-treat analysis in B-cell maturation antigen and CD19 chimeric antigen receptor trials: A systematic review and meta-analysis 2021 ·European Journal of Cancer ·Ghulam Rehman Mohyuddin, (unknown), Nausheen Ahmed, Douglas W. Sborov, Brian McClune, Al‐Ola Abdallah, Aaron M. Goodman, Muhammad Aziz, Isabel Elaine Allen, Vinay Prasad	10
18	Inpatient mortality of patients with multiple myeloma and renal impairment undergoing autologous stem cell transplantation 2020 ·European Journal Of Haematology ·Ghulam Rehman Mohyuddin, Saqib Abbasi, (unknown), Brian McClune, Al‐Ola Abdallah, Siddhartha Ganguly, Joseph P. McGuirk, Leyla Shune	2
19	Outcomes of VD-PACE With Immunomodulatory Agent as a Salvage Therapy for Relapsed/Refractory Multiple Myeloma 2020 ·Clinical Lymphoma Myeloma & Leukemia ·Al‐Ola Abdallah, (unknown), Ghulam Rehman Mohyuddin, (unknown), (unknown), Leyla Shune, Zahra Mahmoudjafari, Joseph P. McGuirk, Siddhartha Ganguly	9
20	Antibiotic prophylaxis for patients with newly diagnosed multiple myeloma: Systematic review and meta‐analysis 2019 ·European Journal Of Haematology ·Ghulam Rehman Mohyuddin, Muhammad Aziz, Brian McClune, Al‐Ola Abdallah, Muzaffar H. Qazilbash	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact